Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
52.80
+0.09 (+0.16%)
Streaming Delayed Price
Updated: 10:58 AM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dianthus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
↗
January 07, 2026
This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure.
Via
The Motley Fool
Topics
Regulatory Compliance
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
December 23, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
November 24, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
November 05, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in Four Investor Conferences During November
November 04, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
October 29, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
October 16, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
October 02, 2025
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized...
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
↗
September 12, 2025
Via
Benzinga
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
↗
September 12, 2025
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
Via
Benzinga
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 11, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
September 09, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Dianthus Therapeutics's Future
↗
September 09, 2025
Via
Benzinga
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
September 08, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
↗
September 08, 2025
The company is working on a treatment for an autoimmune disease that affects the muscles.
Via
Investor's Business Daily
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline
↗
September 08, 2025
Dianthus's claseprubart showed rapid, meaningful improvements in gMG symptoms with a favorable safety profile in Phase 2 MaGic trial results.
Via
Benzinga
Top movers in Monday's pre-market session
↗
September 08, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
September 08, 2025
Via
Benzinga
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
September 08, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
September 07, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
The Oncology Institute Announces Changes to Board of Directors
August 13, 2025
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman
From
Toi Management, LLC
Via
GlobeNewswire
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates
↗
August 07, 2025
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.
Via
Chartmill
Dianthus (DNTH) Q2 Loss Widens 80%
↗
August 07, 2025
Via
The Motley Fool
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
August 07, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
May 29, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
May 22, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
↗
May 13, 2025
Via
Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 12, 2025
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
